Global Leukemia Therapeutics Market 2016-2020


◆タイトル:Global Leukemia Therapeutics Market 2016-2020
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Leukemia
Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Technavio’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche
• Novartis
• Bristol-Myers Squibb
• AbbVie
• Teva Pharmaceuticals

[Other prominent vendors]
• Altor BioScience
• Amgen
• ARIAD Pharmaceuticals
• Arno Therapeutics
• Astex Pharmaceuticals
• AstraZeneca
• Baxter Healthcare
• Bayer HealthCare
• Bellicum Pharmaceuticals
• Biogen
• Boehringer Ingelheim
• BioLineRx
• Boston Biomedical
• Celator Pharmaceuticals
• Celgene
• CTI BioPharma
• Chroma Therapeutics
• Chugai Pharmaceutical
• Cyclacel Pharmaceuticals
• Daiichi Sankyo
• Eisai
• Emergent BioSolutions
• Erytech Pharma
• Fate Therapeutics
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• iDD biotech
• Immune Pharmaceuticals
• Immunomedics
• Infinity Pharmaceuticals
• Innate Pharma
• Jazz Pharmaceuticals
• Juno Therapeutics
• Karyopharm Therapeutics
• Ligand Pharmaceuticals
• MEDA Pharmaceuticals
• MedImmune
• Merck
• Midas Pharma
• Molecular Templates
• MorphoSys
• Nippon Shinyaku
• Novo Nordisk
• Onconova Therapeutics
• Ono Pharmaceuticals
• Orphan Europe
• Otsuka
• Pfizer
• Portola Pharmaceuticals
• Regeneron Pharmaceuticals
• Sanofi
• Sigma-Tau Pharmaceuticals
• Stemline Therapeutics
• Sunesis Pharmaceuticals
• TG Therapeutics
• TheraMAB
• Tolero Pharmaceuticals
• XEME Biopharma
• Xencor
• ZIOPHARM Oncology

[Market driver]
• Technological advances in the monitoring of leukemia
• For a full, detailed list, view our report

[Market challenge]
• Limitations associated with current therapeutic options
• For a full, detailed list, view our report

[Market trend]
• Rise in the development of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
• Market overview
• Total addressable market for global CLL therapeutics
• Vendors in the market

PART 09: Global ALL therapeutics market
• Market overview
• Vendors in the market

PART 10: Global AML therapeutics market
• Market overview
• Vendors in the market

PART 11: Global CML therapeutics market
• Market overview
• Vendors in the market

PART 12: Geographical segmentation
• Global leukemia therapeutics market by geography 2015-2020
• Leukemia therapeutics market in Americas
• Leukemia therapeutics market in EMEA
• Leukemia therapeutics market in APAC

PART 13: Market drivers
• Special regulatory designations for drugs
• Technological advances in the monitoring of leukemia
• Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges
• Complicated disease prognosis
• Financial and infrastructural constraints
• Limitations associated with current therapeutic options
• Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends
• Rise in the development of combination therapies
• Patient assistance programs
• Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 19: Key vendor analysis
• F. Hoffmann-La Roche
• Novartis
• Bristol-Myers Squibb
• AbbVie
• Teva Pharmaceuticals

PART 20: Appendix
• List of abbreviations

PART 21: Explore Technavio


F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.





★調査レポート[白血病治療薬の世界市場:慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病] (Global Leukemia Therapeutics Market 2016-2020 / IRTNTR10286)販売に関する免責事項
[白血病治療薬の世界市場:慢性リンパ性白血病、急性リンパ性白血病、急性骨髄性白血病、慢性骨髄性白血病] (Global Leukemia Therapeutics Market 2016-2020 / IRTNTR10286)についてEメールでお問い合わせ